NCT02882217View on ClinicalTrials.gov

Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Asthma
Interventions
DRUG

XC8 (histamine glutarimide)

DRUG

Placebo

Trial Locations (2)

1130

Karl Landsteiner Institut für experimentelle und klinische Pneumologie, Wolkersbergenstraße 1, Vienna

30625

Fraunhofer Institut für Toxikologie und Experimentelle Medizin ITEM, Feodor-Lynen-Str.15, Hanover

All Listed Sponsors
lead

EURRUS Biotech GmbH

INDUSTRY

NCT02882217 - Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8 | Biotech Hunter | Biotech Hunter